Hideki Kizawa1, 2, Ikuyo Kou1, Aritoshi Iida3, Akihiro Sudo4, Yoshinari Miyamoto1, Akira Fukuda5, Akihiko Mabuchi1, Akihiro Kotani6, Akira Kawakami7, Seizo Yamamoto8, Atsumasa Uchida4, Kozo Nakamura5, Kohei Notoya2, Yusuke Nakamura3
& Shiro Ikegawa11
Laboratory for Bone and Joint Diseases, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN), 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
2
Pharmaceutical Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., 2-17-85 Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan.
3
Laboratory for Genotyping, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN), 1-7-22 Suehirocho, Tsurumi-ku, Yokohama 230-0045, Japan.
4
Department of Orthopaedic Surgery, Mie University Faculty of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.
5
Department of Orthopaedic Surgery, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
6
Department of Orthopaedic Surgery, Kyorin University, School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan.
7
Department of Orthopedic Surgery, Tokyo Teishin Hospital, 2-14-23 Fujimi, Chiyoda-ku, Tokyo 102-8798, Japan.
8
Department of Orthopedic Surgery, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan.
Correspondence should be addressed to Shiro Ikegawa sikegawa@ims.u-tokyo.ac.jp
−mediated expression of the genes aggrecan (AGC1) and type II collagen (COL2A1) and reduced proteoglycan accumulation in an in vitro model of chondrogenesis. The effect on TGF-
